On April 3, 2020, Precision Genetics validated the Emergency Use Authorization (EUA) via the Food and Drug Administration (FDA) to process COVID-19 test kits. Precision Genetics is now available to support state and local healthcare systems in need of public health surveillance and has priority access to test reagents from commercial reagent manufacturers which have received EUA from the FDA.
Precision Genetics provides the test kits for healthcare facilities and providers looking to test patients using real-time RT-polymerase chain reaction (RT-PCR) detection of the SARS-CoV-2 virus (the virus that causes COVID-19) in respiratory specimens. The test uses RT-PCR to detect the virus in upper and lower respiratory specimens.
Test results are intended to be interpreted by a licensed physician or other licensed healthcare professional. Results from this test are not intended to take the place of professional medical advice. Decisions regarding course of medical treatment must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient’s medical history.
Currently, results will be available within 24 hours (1 business day) from time of receipt of the sample in the laboratory, with plans to boost testing capacity in the coming week. Precision Genetics’ healthcare technology laboratory has the capability to direct-connect to other laboratories, healthcare systems, and practitioner’s offices so to deliver test information within seconds of the results being reported. The laboratory uses cloud-based information system, Ovation.io, to help expedite the test orders, specimen tracking and resulting to support faster response times to the COVID-19 pandemic.
If you have any inquiries, please contact us at (877) 843-6544 ext. 4 or email us at COVID19@precisiongenetics.com.